Metastatic Bone Pain Market Size, Share, Industry, Forecast and outlook (2024-2031)

Metastatic Bone Pain Market is Segmented By Drug Type (Non-steroidal Anti-inflammatory Drugs, Opioids, Bisphosphonates, Corticosteroids, Others), By Route of Administration (Oral, Injectable, Transdermal), By End User (Hospitals, Specialty Clinics, Home Care Settings, Ambulatory Surgical Centers, Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2024-2031

Report Overview

Global Metastatic Bone Pain Market reached US$ 14.4 billion in 2023 and is expected to reach US$ 24 billion by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.

Pain is the most common symptom of bone metastases. It tends to be a constant, aching pain that may be worse during activity and can cause sleeping difficulties. Bone pain from cancer tends to be quite different from the pain caused by common conditions such as arthritis or muscular strains.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Rise in the prevalence of cancers

As cancer prevalence increases globally, so does the incidence of bone metastases. Cancers such as breast, prostate, and lung frequently metastasize to bones, leading to a growing need for effective pain management solutions. For instance, according to the American Cancer Society in 2023, the US experienced 1,958,310 new cancer cases and 609,820 deaths, as per the data from central cancer registries and the National Center for Health Statistics, based on population-based cancer occurrence and outcomes.

Complications associated with the drugs

Metastatic bone pain treatments like opioids and radiation therapy have significant side effects, including addiction, tolerance, and health complications. Radiation therapy can cause skin reactions, fatigue, and systemic effects. Surgical interventions, while beneficial in some cases, carry risks of infections, blood loss, and long recovery times. 

Market Segment Analysis

The global metastatic bone pain market is segmented based on drug type, route of administration, end-user, and region.

The NSAIDs from the drug type segment accounted for approximately 47.3%. of the metastatic bone pain  market share

The NSAIDs from the drug type segment accounted for approximately 47.3%. Non-steroidal anti-inflammatory drugs have been in use for the treatment of pain control for all diseases. They also have an anti-inflammatory effect that makes them an ideal drug for the inflammation caused by certain cancer types during extensive tissue invasion and destruction. A Cochrane review by McNicol and colleagues found that NSAIDs appear to be more effective than placebo for cancer pain.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, ongoing clinical trials, FDA approvals, advanced healthcare infrastructure in the region, collaborations and partnerships, and others that help the region to grow during the forecast period.

For instance, in May 2024, the American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology.

• Radiation therapy was strongly recommended to manage pain and other symptoms of bone or spine metastases, including those causing compression of the spinal cord or cauda equina.
• Surgery and dexamethasone combined with radiation therapy were recommended over radiation therapy alone in patients with spine metastases causing spinal cord or cauda equina compression. Postoperative radiation therapy was recommended in patients with non-spine bone metastases requiring surgery.

Market Segmentation

By Drug Type

• Non-steroidal Anti-inflammatory Drugs
• Opioids
• Bisphosphonates
• Corticosteroids
• Others

By Route of Administration

• Oral
• Injectable
• Transdermal

By End User

• Hospitals
• Specialty Clinics
• Home Care Settings
• Ambulatory Surgical Centers
• Others 

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the market include Amgen Inc., Novartis AG, Bayer AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Fresenius Kabi, Stryker Corporation, Medtronic plc, Eli Lilly and Company among others.

Why Purchase the Report?

• To visualize the global metastatic bone pain market segmentation based on drug type, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of the metastatic bone pain market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global metastatic bone pain market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies